Sensei Biotherapeutics (NASDAQ:FTH) Trading 5.4% Higher – Time to Buy?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) rose 5.4% on Tuesday . The stock traded as high as $33.87 and last traded at $34.5250. 9,984 shares traded hands during trading, a decline of 95% from the average daily volume of 211,519 shares. The stock had previously closed at $32.77.

Analyst Ratings Changes

FTH has been the subject of a number of recent analyst reports. Oppenheimer assumed coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Citigroup began coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price objective on the stock. Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a report on Thursday, May 28th. Finally, Wall Street Zen raised Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Price Performance

The stock’s 50 day moving average price is $28.72. The company has a market capitalization of $889.67 million, a PE ratio of -0.24 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, research analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CEO Anand Kiran Parikh purchased 2,806 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were bought at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the transaction, the chief financial officer directly owned 46,688 shares of the company’s stock, valued at $1,097,168. This trade represents a 11.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 49,494 shares of company stock valued at $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after acquiring an additional 1,100 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the first quarter worth approximately $4,188,000. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the second quarter worth $3,610,000. Finally, Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.